• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland

    6/3/25 7:15:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    Unlocking a New Dimension of Personalized Digital Healthcare for Millions Across Europe

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced a significant step in its global expansion through its agreement to acquire ZAVA, a leading digital health platform in Europe. This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon. This acquisition is expected to accelerate Hims & Hers' vision to deliver the same seamless, personalized care experience it has successfully built in the U.S. to millions more people globally. Hims & Hers will establish its own branded presence, leveraging the robust ZAVA platform, in each of these European markets in the coming quarters.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603806947/en/

    This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon.

    This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon.

    By combining ZAVA's trusted European operations, medical rigor, and seamless digital experience with Hims & Hers' proven, trusted brand, the company is poised to become a leader in digital health globally, delivering access to personalized care that meets people where they are. This strategic acquisition will significantly strengthen Hims & Hers' international footprint. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France, and Ireland.

    Hims & Hers will soon introduce a new, personalized dimension of digital health in Europe, providing individuals with access to care tailored to their specific needs and goals across dermatology, weight loss, sexual health and mental health. To ensure a world-class and localized experience, this expansion will include access to British, German, and French healthcare providers in local languages. While Hims & Hers will share more about the offerings and their rollout in the coming months, they expect the deal to be accretive by 2026.

    "The demand for simpler, more personalized healthcare is universal," said Andrew Dudum, founder and CEO of Hims & Hers. "By leveraging ZAVA's established European presence, cutting-edge technology, and deep customer understanding, we're poised to fundamentally transform access to care for millions across Europe. Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve."

    "Wherever you live, the need is the same: healthcare that's personal, trustworthy and fast. By joining forces with Hims & Hers, we can put that standard within reach of millions more people across Europe," said David Meinertz, co-founder and CEO of ZAVA. "Together we'll pair ZAVA's trusted clinical services, established footprint, and deep understanding of the European healthcare landscape with the Hims & Hers experience to make affordable access to high-quality, personalized care the rule, not the exception. I'm thrilled to be working with Andrew and his team. It's still day one for digital healthcare, and I can't wait to see what we'll achieve for patients in the years ahead."

    The acquisition consideration will be comprised of 100% cash, to be funded from the company's balance sheet at closing. The acquisition is expected to close in the second half of 2025, and Hims & Hers expects to continue expanding globally as demand for personalized healthcare continues to grow.

    For more information, please see news.hims.com.

    About Hims & Hers Health, Inc

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

    About ZAVA

    ZAVA is a leading digital health platform in Europe, on a mission to make high-quality, dependable healthcare accessible and affordable. Serving more than 1.3 million active customers, ZAVA's in-house medical team delivered nearly 2.3 million consultations in 2024 across the UK, Germany, France and Ireland - putting compassionate, clinically-robust healthcare in people's hands 24/7. Rated "outstanding" for leadership by the UK Care Quality Commission, ZAVA combines medical rigour with a friction-free digital experience. ZAVA's comprehensive service portfolio spans weight management, women's and men's health, sexual health, general medicine and skin & hair care - helping people tackle both everyday and sensitive conditions quickly, discreetly and safely.

    Cautionary Note Regarding Forward-Looking Statements

    Except for historical information, certain statements in this press release, including statements regarding the timing and effects of entering into the acquisition described above, our future performance, anticipated customer demand, the ability to scale our business, the solutions accessible on our platform, and the underlying assumptions with respect to the foregoing, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks, uncertainties and assumptions about Hims & Hers and its business. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions, our legal and regulatory environment, macroeconomic and geopolitical factors, and those factors described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the "Commission"). Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250603806947/en/

    Press Contact

    Susan Cadrecha

    [email protected]

    Get the next $HIMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    6/4/2025$61.00 → $65.00Buy
    Needham
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    1/7/2025$35.00Buy
    BTIG Research
    12/17/2024$42.00Overweight
    Morgan Stanley
    11/14/2024Buy → Underperform
    BofA Securities
    8/22/2024$24.00Buy
    Needham
    More analyst ratings

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hims & Hers Announces Plans to Acquire ZAVA, Accelerating Major European Growth Across the UK, Germany, France, and Ireland

      Unlocking a New Dimension of Personalized Digital Healthcare for Millions Across Europe Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced a significant step in its global expansion through its agreement to acquire ZAVA, a leading digital health platform in Europe. This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon. This acquisition is expected to accelerate Hims & Hers' vision to deliver the same seamless, personalized care experience it has successfully built in the U.S. to millions more people globally. Hims

      6/3/25 7:15:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Introduces 6-Month Wegovy® New Customer Offer

      Hims & Hers Health, Inc. (NYSE:HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522903885/en/Starting today, new customers eligible for Wegovy® on the Hims & Hers platform can access their care for $549 per month for 6 months (for a limited-time only). "We are always looking for long-term, sustainable ways to increase access to care for our customers," said Andrew Dudum, CEO and co-founder of

      5/22/25 3:39:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

      Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased

      5/8/25 10:25:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    SEC Filings

    See more
    • Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

      8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/13/25 5:23:44 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health Inc. filed SEC Form 8-K: Other Events

      8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/9/25 7:00:17 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by Hims & Hers Health Inc.

      10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/5/25 4:17:34 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/12/24 3:52:47 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/4/24 1:33:02 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/4/24 12:09:24 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HIMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Chief Financial Officer Okupe Oluyemi exercised 6,437 shares at a strike of $5.01 and sold $613,537 worth of shares (11,581 units at $52.98), decreasing direct ownership by 66% to 39,153 units (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/30/25 4:28:11 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form 4 filed by Chief Financial Officer Okupe Oluyemi

      4/A - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/29/25 5:56:24 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Legal Officer Boughton Soleil sold $180,628 worth of shares (3,233 units at $55.87), decreasing direct ownership by 2% to 153,194 units (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/29/25 5:56:14 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

      Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

      5/8/25 6:50:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

      Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne

      5/5/25 9:01:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Define Ventures Appoints Carolyn Magill as Venture Partner

      The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

      3/11/25 5:30:00 AM ET
      $EVH
      $HIMS
      $LVGO
      Other Consumer Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      11/14/24 4:57:45 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/22/24 4:16:26 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Hims & Hers Health with a new price target

      Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $65.00 from $61.00 previously

      6/4/25 7:59:55 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by TD Cowen with a new price target

      TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00

      4/29/25 8:05:51 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Hims & Hers Health from Overweight to Equal-Weight and set a new price target of $60.00 from $42.00 previously

      2/18/25 7:09:28 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Financials

    Live finance-specific insights

    See more
    • Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

      Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.him

      5/5/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025

      Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 5, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management team

      4/14/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% year-over-year in 2024 Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com. "2024 was a fantastic year at Hims and Hers as we con

      2/24/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care